Anupam Rishi, MD

  Anupam Rishi, MD, is an Assistant Member at Moffitt Cancer Center, Department of Radiation Oncology, with focus on Genitourinary and Gynecologic malignancies, specializing in brachytherapy. Dr. Rishi received his medical degree at Calcutta University in India, following which he completed Residency in Radiation Oncology from Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh and Senior Residency/Registrar at Tata Memorial Hospital, Mumbai, India, one of the largest and busiest academic cancer hospital in Asia. Subsequently, Dr Rishi completed multiple specialized fellowships, including Head-Neck Oncology Fellowship from esteemed Princess Margaret Hospital, Toronto, Canada, followed by Advanced Radiation Oncology Fellowship and Brachytherapy Fellowship from Moffitt Cancer Center. Thereafter, Dr Rishi completed a General Surgery internship and Second Radiation Oncology Residency from Moffitt Cancer Center/University of South Florida, where he also served as Chief Resident. Dr. Rishi’s clinical interests include genitourinary, gynecologic malignancies and brachytherapy. Dr. Rishi stands out as one of the few brachytherapy-fellowship trained radiation oncologists in country practicing image-guided brachytherapy which involves internal radiation therapy delivering high-dose radiation accurately to the target tissue and while limiting radiation to normal tissues. Brachytherapy offers a safe and effective treatment option for various cancer types, including prostate (monotherapy and as boost), penile cancer, gynecologic, sarcoma, gastrointestinal and cutaneous malignancies. Studies have demonstrated that combined EBRT and brachytherapy yields superior cancer control outcomes compared to EBRT alone in unfavorable-intermediate and high-risk organ confined prostate cancer. In addition, Dr Rishi has profound interest in research and education, and has participated in multiple research projects with over 50 peer-reviewed publications, presented his research nationally and internationally, and received multiple awards including American Society of Radiation Oncology (ASTRO) Recognition Award. His research interest includes novel brachytherapy treatment techniques, definitive IMRT in vulvar cancer, radiomics and use of technological strategies to improve radiation delivery and patient experiences. He is currently leading a multi-institutional collaborative ‘DRIVE’ study evaluating high-dose definitive IMRT in vulvar cancer.    

• Panda G, Kalra B, Rishi A, Khanna N, Kakoti S, Sridhar E, Shet T, Sengar M, Nayak L, Bagal B, Jain H, Laskar SS, Goda JS. Long-Term Clinical Outcomes and Sequelae of Therapy in Early-Stage Orbital Mucosa-Associated Lymphoid Tissue Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):513-522. Pubmedid: 35027338.
• Rishi A, Saini AS, Spiess PE, Yu A, Fernandez DC, Johnstone PAS, Naghavi AO. Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer. Brachytherapy. 2022 Aug.21(6):839-847. Pubmedid: 35915039.
• Barakat E, Bibok A, Rishi A, Ahmed A, Frakes JM, Hoffe SE, Armaghani AJ, Soyano AE, Costa RLB, El-Haddad G, Choi J, Kis B. Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study. Adv Radiat Oncol. 2021 Oct.7(1):100838. Pubmedid: 35071835. Pmcid: PMC8767250.
• McDonald J, Chuang CY, Hicks JK, Berry DK, Imanirad I, Rishi A, Frakes JM, Hoffe SE, Felder S. FANCD2 Mutation in a Patient With Early Rectal Cancer Receiving Definitive Chemoradiation. Adv Radiat Oncol. 2021 May.6(5):100717. Pubmedid: 34258475. Pmcid: PMC8260782.
• Yuan Z, Frazer M, Rishi A, Latifi K, Tomaszewski MR, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Zhang GG, Frakes JM. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Rep Pract Oncol Radiother. 2021 Feb.26(1):29-34. Pubmedid: 33948299. Pmcid: PMC8086711.
• Krzyston H, Morse B, Deperalta D, Rishi A, Kayaleh R, El-Haddad G, Smith J, Druta M, Kis B. Liver-directed treatments of liver-dominant metastatic leiomyosarcoma. Diagn Interv Radiol. 2020 Sep.26(5):449-455. Pubmedid: 32673206. Pmcid: PMC7490031.
• Kayaleh R, Krzyston H, Rishi A, Naziri J, Frakes J, Choi J, El-Haddad G, Parikh N, Sweeney J, Kis B. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study. J Vasc Interv Radiol. 2020 Jul.31(7):1060-1068. Pubmedid: 32534978.
• Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, Hoffman MS, Apte SM, Shahzad MMK, Chon HS, Chern JY, Wenham RM, Montejo ME. High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Gynecol Oncol. 2020 Feb.156(2):349-356. Pubmedid: 31771865.
• Rishi A, Zhang GG, Yuan Z, Sim AJ, Song EY, Moros EG, Tomaszewski MR, Latifi K, Pimiento JM, Fontaine JP, Mehta R, Harrison LB, Hoffe SE, Frakes JM. Pretreatment CT and 18 F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer. J Med Imaging Radiat Oncol. 2020 Dec.65(1):102-111. Pubmedid: 33258556.
• Sunderland MS, Dakwar A, Rishi A, Bennett RD. Pneumoperitoneum, Pneumoretroperitoneum, and Pneumoscrotum Following Transanal Excision of Rectal Polyp. Am Surg. 2020 Dec. Pubmedid: 33342273.
• Rishi A, Yu HM. Current Treatment of Melanoma Brain Metastasis. CURR TREAT OPTION ON. 2020 Apr.21(6):45. Pubmedid: 32350685.
• Yang GQ, Mhaskar R, Rishi A, Naghavi AO, Frakes JM, Almhanna K, Fontaine J, Pimiento JM, Hoffe SE. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy. Dis Esophagus. 2018 Dec.32(8). Pubmedid: 30597022.
• Rishi A, Hui Huang S, O'Sullivan B, Goldstein DP, Lu L, Ringash J, Waldron J, Wells W, Sun A, Hope A, Chung P, Giuliani M, Spreafico A, Tong L, Xu W, Bayley A. Outcome following radiotherapy for head and neck basal cell carcinoma with 'aggressive' features. Oral Oncol. 2017 Sep.72:157-164. Pubmedid: 28797452.
• Caudell JJ, Torres-Roca JF, Gillies RJ, Enderling H, Kim S, Rishi A, Moros EG, Harrison LB. The future of personalised radiotherapy for head and neck cancer. Lancet Oncol. 2017 May.18(5):e266-e273. Pubmedid: 28456586. Pmcid: PMC7771279.
• Wadasadawala T, Kannan S, Gudi S, Rishi A, Budrukkar A, Parmar V, Shet T, Desai S, Gupta S, Badwe R, Sarin R. Predicting loco-regional recurrence risk in T1, T2 breast cancer with 1-3 positive axillary nodes postmastectomy: Development of a predictive nomogram. Indian J Cancer. 2017 Jan.54(1):352-357. Pubmedid: 29199721.
• Jalali R, Rishi A, Goda JS, Sridhar E, Gurav M, Sharma P, Moiyadi A, Shetty P, Gupta T. Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children. Neurooncol Pract. 2016 Mar.3(1):39-47. Pubmedid: 31579520. Pmcid: PMC6760342.
• Murthy V, Rishi A, Gupta S, Kannan S, Mahantshetty U, Tongaonkar H, Bakshi G, Prabhash K, Bhanushali P, Shinde B, Inamdar N, Shrivastava S. Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer. Clin Biochem. 2016 Jan.49(1-2):79-84. Pubmedid: 26506115.
• Hosni A, Dixon PR, Rishi A, Au M, Xu W, Song Y, Chepeha DB, Goldstein DP, Huang SH, Kim J, O'Sullivan B, Waldron J, Bratman SV, de Almeida JR. Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma. JAMA Otolaryngol Head Neck Surg. 2016 Dec.142(12):1208-1215. Pubmedid: 27812692.
• Rishi A, Ghoshal S. Acute multiple arterial thrombosis after cisplatin in base of tongue carcinoma: case report. Head Neck. 2013 Sep.35(9):E269-E271. Pubmedid: 22915348.
• Rishi A, Ghoshal S, Verma R, Oinam AS, Patil VM, Mohinder R, Sharma SC. Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: a phase III randomised trial. Radiother Oncol. 2013 Jun.107(3):317-324. Pubmedid: 23746674.